TABLE 1.
Adalimumab biosimilars approved by the European Medicines Agency for use in the European Union as of September 2020 (European Medicines Agency, 2020).
| Brand name | Marketing authorization holder | Marketing authorization date |
|---|---|---|
| Amgevita® | Amgen | March 21, 2017 |
| Imraldi® | Samsung Bioepis | August 24, 2017 |
| Hyrimoz®/Hefiya®/Halimatoz® a | Sandoz | July 26, 2018 |
| Hulio® | Mylan | September 16, 2018 |
| Idacio® | Fresenius Kabi | April 02, 2019 |
| Amsparity® | Pfizer | February 13, 2020 |
a
Different brand names might be used as a marketing strategy or to circumvent potential patent issues via different indications on the label.